

# Conjugated linoleic acid (CLA) and obesity

Manuela-Belén Silveira<sup>1,\*</sup>, Raffaele Carraro<sup>1</sup>, Susana Monereo<sup>2</sup> and Javier Tébar<sup>3</sup>

<sup>1</sup>Servicio de Endocrinología y Nutrición, Hospital Universitario de La Princesa, Diego de León, 62. 28006 Madrid, Spain: <sup>2</sup>Sección de Endocrinología y Nutrición, Hospital Universitario de Getafe, Madrid, Spain:

<sup>3</sup>Servicio de Endocrinología y Nutrición, Hospital Universitario Virgen de La Arrixaca, Murcia, Spain

Submitted November 2006; Accepted April 2007

## Abstract

**Background:** The term conjugated linoleic acid (CLA) refers to several positional and geometric conjugated dienoic isomers of linoleic acid (LA), of which the trans-10,cis-12 isomer has been reported to reduce adiposity and increase lean mass in mice and other animals when included at  $\leq 1\%$  of the diet. However, most dietary CLA in humans is obtained from dairy products, accounting for the cis-9,trans-11 CLA isomer, also known as rumenic acid, for more than 90% of the total CLA intake. Commercial CLA preparations industrially produced, containing trans-10,cis-12 and cis-9,trans-11 CLA isomers in diverse proportions, are attracting consumers' interest because of the purported body fat-lowering effects of CLA, coupled to the perception of a 'natural' compound devoid of harmful effects. Nevertheless, despite numerous studies on CLA effects on body composition for nearly a decade, the mechanisms by which CLA isomers elicit their effects remain largely unknown. The purpose of this paper is to provide an updated review of the studies performed on animals and humans, as well as to describe the potential mechanisms involved in CLA effects on body weight and composition and metabolism.

**Method:** Literature review.

**Results:** Experiments in humans have not been able to show a significant effect on body weight, body composition or weight regain related to either of the CLA isomers. In fact, some studies suggest a tendency towards a decrease in body fat mass and an increase in body lean mass, while some others raise concern about the possibility of deleterious effects of trans-10,cis-12 CLA on lipid profile, glucose metabolism and insulin sensitivity.

**Conclusions:** Evidence regarding effectiveness of CLA in humans is not concluding.

**Keywords**  
CLA fatty acid  
Obesity  
Anti-obesity agents  
Body composition  
Lipid metabolism  
Insulin resistance  
Diabetes mellitus type 2

The term conjugated linoleic acid (CLA) refers to several positional and geometric conjugated dienoic isomers of linoleic acid (LA). LA, or cis,cis-9, 12-octadecadienoic acid, is an 18-carbon omega-6 fatty acid (18:2, 9c-12c) abundant in seed oils, such as sunflower oil. LA is converted to CLA when a chemical or microbial reaction shifts the double bonds to form alternating double and single bonds, hence the term *conjugated*. These double bonds can be located in different positions along the 18-carbon chain (7,9; 8,10; 9,11; 10,12; 11,13). This conjugation of the double bonds can alter the geometrical isomery of the acid, so that one or both double bonds can adopt trans isomery. The two isomers with known biological activity are cis-9,trans-11 and trans-10,cis-12 CLA.

CLA potential effects on health include anticarcinogenic, antiatherogenic, antidiabetogenic and immune modulating properties<sup>1,2</sup>. CLA has also attracted interest in the scientific community because of its potential effects on body composition, reducing body fat mass and increasing the lean mass. Because of the increasing prevalence and incidence

of obesity, a significant proportion of consumers are interested in CLA supplements with purported body fat-lowering effects, perceived as a 'natural' compound devoid of harmful effects.

## Sources of conjugated linoleic acid

Rumiant animals are able to synthesise CLA through the microbial isomerisation (*Butyrivibrio fibrisolvens* and other anaerobic bacteria) of dietary LA in their gastrointestinal tracts<sup>3</sup>. Rumiant meat (beef, veal, lamb) and dairy products are rich in cis-9,trans-11 CLA, also known as rumenic acid. Rumenic acid is the first intermediate step in the biohydrogenation of LA to stearic acid (C18:0).

CLA isomers can also be industrially produced by heating LA in the presence of alkali or by partial hydrogenation of LA. CLA that is typically produced for experimental purposes (MI-CLA) consists of the cis-9,trans-11 (40.8–41.1%), trans-10,cis-12 (43.5–44.9%)

\*Corresponding author: Email belensilveira@telefonica.net

**Table 1** Effects of CLA isomers on body weight and composition

	Animals (mice and others)	Humans
Trans-10,cis-12 CLA	↓ body fat mass <sup>10–14</sup> ↑ body lean mass <sup>10–14</sup> ↓ body weight <sup>10–14</sup>	No effects on body weight <sup>23–26</sup> No effects on weight regain <sup>27,28</sup> ↓ body fat mass? <sup>30–33</sup> ↑ body lean mass? <sup>27,29,30–33</sup>
Cis-9,trans-11 CLA	↑ feed efficiency and growth in weanling animals <sup>10,14,18–20</sup>	

CLA – conjugated linoleic acid.  
 ↑ – increase; ↓ – decrease; ? – possible.

and trans-9,trans-11/trans-10,trans-12 (4.6–10%) isomers<sup>4</sup>. It should be noted that some commercial CLA preparations contain additional isomers with conjugated double bonds at the 8,10 or 11,13 positions<sup>5</sup>.

The major dietary sources of CLA for humans are beef and dairy products. Cis-9,trans-11 CLA is the principal CLA isomer in milkfat<sup>4</sup>. Several factors influence CLA content of food products, such as animal's diet, age, breed or seasonal factors, reaching the highest levels in cow's milk during the spring and summer, as cows are allowed to graze in pastures<sup>6</sup>. CLA in milk or meat is a stable compound under normal cooking and storage conditions<sup>7</sup>.

Total CLA content in milk or dairy products ranges from 0.34% to 1.07% of total fat<sup>7</sup>, whereas in raw or processed beef it ranges from 0.12% to 0.68% of total fat<sup>7</sup>. CLA daily intakes are 212 mg for men and 151 mg for women not consuming CLA commercial preparations. Most dietary CLA is obtained from dairy products, accounting for the cis-9,trans-11 CLA isomer for more than 90% of the total CLA intake<sup>8</sup>.

### Evidence of conjugated linoleic acid effects on body weight in animals

Interest in CLA started in 1987, when Ha *et al.*<sup>9</sup> reported that CLA present in fried ground beef, also synthetically produced by base-catalysed isomerisation of LA, was an effective inhibitor of benzopyrene-initiated mouse epidermal neoplasia.

Regarding obesity and body composition, several studies in animals have shown the ability of CLA to reduce adiposity and increase lean mass. Park *et al.*<sup>10</sup> were the first to report that dietary CLA could alter body composition. A diet containing 0.5% MI-CLA administered to the ICR (Institute for Cancer Research) line of mice caused a 60% decrease in body fat, coupled with enhanced lean body mass, after about 4–5 weeks of feeding.

CLA has also been reported to lower fat mass in other lines of mice<sup>4</sup>, as well as in Sprague–Dawley<sup>11</sup> and Zucker rats<sup>12</sup>, though not reaching such impressive results as in mice. In swine, MI-CLA decreased fat deposition and increased lean tissue too<sup>13,14</sup>. Interestingly, MI-CLA-supplemented diet increased fat deposition in obese Zucker rats<sup>12</sup>, while reducing insulin levels.

CLA does not reduce food intake in rodents<sup>15,16</sup> and its effects are independent of fat content of the diet<sup>15</sup>.

Conversely, dietary protein source may alter the effects of CLA on adipocytes' fat content and adipocytokine production, as rats fed with soy diet show more pronounced fat loss and different changes in leptin and adiponectin levels compared to their casein-fed counterparts<sup>17</sup>.

There is substantial evidence that CLA reduces body fat gain in young growing animals<sup>10,14,18–20</sup> although some study results do not strongly confirm this<sup>21</sup>. CLA supplementation during gestation and lactation elicits greater body weight and feed efficiency in weanling mice relative to control animals<sup>22</sup>. This effect on feed efficiency and growth seems to be exerted by the cis-9,trans-11 isomer<sup>4</sup>.

Reported effects of CLA on body weight and composition in animals are summarised in Table 1.

### Evidence of conjugated linoleic acid effects on body weight in humans

Experiments in humans have not been able to show a significant effect on body weight related to either MI-, cis-9,trans-11 or trans-10,cis-12 CLA<sup>23–26</sup>. Published studies report contradicting results. Although in the majority of them there are no significant differences on body weight, body composition<sup>26</sup> or weight regain<sup>27,28</sup> between controls and CLA-supplemented groups, some studies suggest that CLA might have a tendency to increase lean body mass<sup>27,29,30</sup>. On one hand, one study carried out in overweight/obese adult volunteers<sup>30</sup> report a reduction in body fat mass with doses  $\geq 3.4$  g MI-CLA per day at week 12 (150–580 g more than placebo), with a significant increase in body lean mass in the group that received 6.8 g MI-CLA per day, measured by dual-energy X-ray absorptiometry; however, this group was also the only one with a significant increase in exercise level. Similar effects were detected in other human trials with MI- and trans-10,cis-12 CLA<sup>31</sup>.

On the other hand, another recent study designed to assess the effect of 1-year supplementation with 3.4 g day<sup>-1</sup> CLA in body weight or body fat regain found no differences against placebo<sup>28,32</sup>. In a recent meta-analysis at a dose of 3.2 g day<sup>-1</sup>, CLA was found to produce a slight reduction in fat mass peaking at 6 months, although confidence intervals were broad.

Differences in doses (ranging from 0.7 to 6.8 g day<sup>-1</sup>)<sup>30–33</sup>, treatment compliance, type and/or proportion

of the administered isomer/s, length of the study, characteristics of the study population, energy expenditure and nutrient and energy intakes are possible explanations for the observed discrepancies in the results. Noteworthy, there is no clear dose–response related to the body fat-lowering effect of trans-10,cis-12 CLA and in most of the studies that reported a significant decrease of body fat mass or in those suggesting an increase in lean mass, the participants were also involved in a training programme or did a considerable amount of exercise<sup>30,33</sup>. Therefore, exercise might enhance the body fat lowering and/or lean mass increasing effect of CLA.

The effects of CLA on body weight and composition in humans are summarised in Table 1.

### Effects of conjugated linoleic acid on adipocytes

Although the mechanisms by which CLA exerts its action on body weight have not been fully elucidated yet, it seems clear that trans-10,cis-12 CLA is the isomer involved in the changes of body composition.

Trans-10,cis-12 CLA and/or its metabolites is/are able to reduce lipid uptake by adipocytes due to the inhibitory effects on gene expression and enzymatic activity of stearoyl-CoA desaturase (SCD)<sup>34,35</sup> and lipoprotein lipase (LPL)<sup>10,36,37</sup>. Trans-10,cis-12 CLA also inhibits the expression of glucose transporter-4 (GLUT-4)<sup>37,38</sup> and increases the activity of carnitine palmitoyltransferase (CPT), enhancing fatty acid oxidation<sup>10</sup>. Trans-10,cis-12 CLA reduces lipogenesis in human<sup>37</sup> and mice adipocytes, decreasing sterol regulatory element-binding protein-1 (SREBP-1) expression *in vivo*<sup>39</sup>. Trans-10,cis-12 CLA also induces adipocyte apoptosis in mice<sup>39–43</sup>, perhaps mediated by an increase in tumour necrosis factor alpha (TNF $\alpha$ )<sup>39</sup>, but the effects of CLA on lipolysis *in vivo* and *in vitro* are conflicting<sup>10,38</sup>. Data regarding its effects on preadipocyte differentiation are inconclusive, possibly depending on species, CLA isomer and experimental conditions<sup>4,37</sup>. Chronic treatment with trans-10,cis-12 CLA significantly reduces the expression of several adipocyte-specific genes, including PPAR $\alpha$  and PPAR $\gamma$  target genes, partly due to an increase in nuclear factor kappa B (NF $\kappa$ B) activity and subsequent induction of interleukin-6<sup>44</sup>, therefore explaining at least part of its effects on glucose and lipid metabolism. Trans-10,cis-12 CLA inhibits insulin-stimulated glucose uptake and oxidation, reduces fatty acid uptake and alters fatty acid metabolism in differentiating human preadipocytes<sup>37</sup>.

MI-CLA appears to increase energy expenditure in rodents by several mechanisms that are not fully understood, although an increase in uncoupling protein UCP1 and UCP3 gene expression does not seem to be involved<sup>4,15,16,45,46</sup>. However, some studies show an increase in UCP2 expression (mostly with trans-10,cis-12 CLA supplementation) in brown and white adipose tissue and skeletal muscle<sup>39,47,48</sup>.

**Table 2** Effects of trans-10,cis-12 CLA on adipocytes

Effect	Potential mechanism
↓ lipid uptake	↓ SCD <sup>34,35</sup> and LPL <sup>10,36,37</sup>
↓ glucose uptake	↓ GLUT4 <sup>37–38</sup>
↑ fatty acid oxidation	↑ CPT <sup>10</sup>
↓ lipogenesis	↓ SREBP-1 <sup>39</sup>
↑ apoptosis	↓ TNF $\alpha$ ? <sup>39</sup>
↑ energy expenditure	↑ UCP2? <sup>39,47,48</sup>
differentiation?	↑ NF $\kappa$ B?
lipolysis?	↓ PPAR target genes? <sup>44</sup>

CLA – conjugated linoleic acid; SCD – stearoyl-CoA desaturase; LPL – lipoprotein lipase; GLUT4 – glucose transporter-4; CPT – carnitine palmitoyltransferase; SREBP-1 – sterol regulatory element-binding protein-1; TNF $\alpha$  – tumour necrosis factor alpha; UCP2 – uncoupling protein 2; NF $\kappa$ B – nuclear factor kappa B; PPAR – peroxisome proliferator-activated receptor. ↑ – increase; ↓ – decrease; ? – possible.

According to all these data, it seems that trans-10,cis-12 CLA elicits its de-lipidative activity through both metabolism and cell cycle control. More research is necessary to clarify conflicting results and differences between species.

Potential effects of CLA on adipocytes are summarised in Table 2.

### Effects of conjugated linoleic acid on the liver and skeletal muscle

Several *in vivo* and *in vitro* studies in mice have reported an increase in both liver fatty acid synthesis and oxidation in response to MI-CLA supplementation<sup>39,49–51</sup>. CLA may mediate its effects through PPAR $\alpha$  and PPAR $\beta/\delta$  (both trans-10,cis-12 and cis-9,trans-11 CLA isomers are their ligands<sup>52</sup>), a decrease in SCD-1<sup>53</sup> expression and other alternative pathways, as suggested by studies on knock-out mice<sup>54,51</sup>. However, there seem to be differences between species, as hamsters<sup>55</sup> on a CLA-supplemented diet developed liver hypertrophy but not lipid accumulation, and rats or pigs fed with CLA-enriched diets showed no changes in weight or lipid content in the liver<sup>4</sup>.

There is evidence of the anabolic properties of CLA on lean mass in mice<sup>10</sup>, and probably in other species<sup>56,57</sup>. However, the effects of CLA on the skeletal muscle are still unclear. CLA-fed mice showed an increase of CPT activity on skeletal muscle, improving  $\beta$ -oxidation<sup>10</sup> and, as previously indicated, an enhancement in UCP2 expression is also evident in some studies.

### Metabolic effects of conjugated linoleic acid

The effects on lipid metabolism of trans-10,cis-12 CLA, the active isomer involved in fat mass loss, are currently objects of concern. Administration of trans-10,cis-12 CLA to humans results in an increase of the LDL/HDL ratio<sup>24</sup>, some studies reflecting an increase in LDL-cholesterol<sup>29</sup>, while others showing a decrease in HDL-cholesterol<sup>29,30,33,58</sup>; however, such effects are just marginal and

not statistically significant compared to the control group in some of the studies<sup>29,33</sup>. These deleterious effects are not evident with the administration of MI-CLA or the cis-9,trans-11 isomer<sup>24,25,31,58–60</sup>. Moreover, cis-9,trans-11 CLA actually appears to decrease LDL cholesterol in humans<sup>24,30</sup>. A 6.4 g day<sup>-1</sup> MI-CLA doses for 12 weeks produced a modest increase in lean mass (0.6 kg) but significant decrease in serum HDL-cholesterol, sodium, hemoglobin, and hematocrit, and significant increases in serum alkaline phosphatase, C-reactive protein, and K-6, and white blood cells.

Plasma triacylglycerides (TAG) did not significantly change or decrease compared to placebo in some studies with MI-CLA supplementation<sup>33,59,62,63</sup>. Nevertheless, in another study mean plasma TAG concentration was higher during supplementation with a mixture 85% trans-10,cis-12 CLA than with another mixture 80% cis-9,trans-11 CLA<sup>24</sup>.

Interestingly, there is no clear dose–response relationship in the relative hyperlipidemic properties of trans-10, cis-12 CLA and hypolipidemic properties of cis-9,trans-11 CLA in humans<sup>24</sup>, suggesting that this influence could be exerted even at low doses<sup>24</sup>. Moreover, in apolipoprotein E knockout mice, supplementation with trans-10,cis-12 CLA had a profound pro-atherogenic effect, whereas cis-9,trans-11 CLA impeded the development of atherosclerosis<sup>64</sup>.

In a similar way, there are conflicting results related to carbohydrate metabolism in humans. Although several studies show that neither cis-9,trans-11 CLA nor trans-10,cis-12 CLA supplementation significantly modify plasma glucose or insulin levels or alter insulin sensitivity (revised QUICKI) or insulin resistance (HOMA-IR)<sup>24,29,59</sup>, Riserus *et al.*<sup>31,58,65</sup> repeatedly report marginal but detrimental effects of both trans-10,cis-12 CLA (3.4 g day<sup>-1</sup>) and cis-9,trans-11 CLA (3 g day<sup>-1</sup>) on insulin sensitivity (measured as the insulin sensitivity index with the euglycemic clamp) and lipid peroxidation in obese subjects with metabolic syndrome. Another study in type 2 diabetic patients supplemented with MI-CLA (3 g day<sup>-1</sup>) also shows unfavourable effects on fasting glucose, insulin resistance (HOMA) and oral glucose insulin sensitivity<sup>60</sup>. These results are in agreement with those of CLA-fed mice<sup>39</sup>, but not with the reported improvement on insulin sensitivity of some other studies in genetically obese mice<sup>66</sup> or Zucker rats supplemented with CLA<sup>12</sup>.

## Conclusions

Although there is evidence in animals of the ability of trans-10,cis-12 CLA to reduce adiposity and increase lean mass, such unequivocal data supporting the efficacy of either of the CLA isomers in humans are not available.

Moreover, contradictory results raise concern about the possibility of the deleterious effects of trans-10,cis-12 CLA

on the lipid profile, glucose metabolism and insulin sensitivity. Therefore, it is advisable to consider with caution the use of CLA supplements containing high quantities of trans-10,cis-12 CLA, especially in obese patients with type 2 diabetes or metabolic syndrome, which constitutes a considerable proportion of the whole overweight/obese population.

Before CLA supplementation is recommended, further research on human effectiveness and safety of the different isomers of CLA is required.

## Acknowledgements

*Conflict of interest declaration:* The authors had no conflicts of interest to report.

*Authorship contributions:* All the authors (M.B.S., R.C., S.M., J.T.) declare that they participated sufficiently in the work to take full and public responsibility for its content..

## References

- 1 Belury MA. Inhibition of carcinogenesis by conjugated linoleic acid: potential mechanisms of action. *Nutrition* 2002; **132**(10): 2995–8.
- 2 McLeod RS, LeBlanc AM, Langille MA, Mitchell PL, Currie DL. Conjugated linoleic acids, atherosclerosis, and hepatic very-low-density lipoprotein metabolism. *American Journal of Clinical Nutrition* 2004; **79**: 1169S–74S.
- 3 Kepler CR, Hirons KP, McNeill JJ, Tove SB. Intermediates and products of the biohydrogenation of linoleic acid by *Butyrivibrio fibrisolvens*. *The Journal of Biological Chemistry* 1966; **241**(6): 1350–4.
- 4 Pariza MW, Park Y, Cook ME. The biologically active isomers of conjugated linoleic acid. *Progress in Lipid Research* 2001; **40**(4): 283–98.
- 5 Christie WW, Dobson G, Gunstone FD. Isomers in commercial samples of conjugated linoleic acid. *Lipids* 1997; **32**(11): 1231.
- 6 Rainer L, Heiss C. Conjugated Linoleic Acid: health implications and effects on body composition. *Journal of the American Dietetic Association* 2004; **104**: 936–8.
- 7 Dhiman TR, Nam SH, Ure AL. Factors affecting conjugated linoleic acid content in milk and meat. *Critical Reviews in Food Science and Nutrition* 2005; **45**(6): 463–82.
- 8 Ritzenthaler KL, McGuire MK, Falen R, Schultz TD, Dasgupta N, McGuire MA. Estimation of conjugated linoleic acid intake by written dietary assessment methodologies underestimates actual intake evaluated by food duplicate methodology. *Journal of Nutrition* 2001; **131**: 1548–54.
- 9 Ha YL, Grimm NK, Pariza MW. Anticarcinogens from fried ground beef: heat-altered derivatives of linoleic acid. *Carcinogenesis* 1987; **8**: 1881–7.
- 10 Park Y, Albright KJ, Liu W, Storkson JM, Cook ME, Pariza MW. Effect of conjugated linoleic acid on body composition in mice. *Lipids* 1997; **32**: 853–8.
- 11 Yamasaki M, Ikeda A, Oji M, Tanaka Y, Hirao A, Kasai M, *et al.* Modulation of body fat and serum leptin levels by dietary conjugated linoleic acid in Sprague–Dawley rats fed various fat-level diets. *Nutrition* 2003; **19**: 30–5.
- 12 Sisk MB, Hausman DB, Martin RJ, Azain MJ. Dietary conjugated linoleic acid reduces adiposity in lean but

- not obese Zucker rats. *Journal of Nutrition* 2001; **131**: 1668–74.
- 13 Dugan MER, Aalhus JL, Schaefer AL, Kramer JKG. The effect of conjugated linoleic acid on fat to lean repartitioning and feed conversion in pigs. *Canadian Journal of Animal Science* 1997; **77**: 723–5.
  - 14 Ostrowska E, Muralitharan M, Cross RF, Bauman DE, Dunshea FR. Dietary conjugated linoleic acids increase lean tissue and decrease fat deposition in growing pigs. *Journal of Nutrition* 1999; **129**: 2037–42.
  - 15 DeLany JP, West DB. Changes in body composition with conjugated linoleic acid. *Journal of the American College of Nutrition* 2000; **19**: 487S–93S.
  - 16 West DB, Blohm FY, Truett AA, DeLany JP. Conjugated linoleic acid persistently increases total energy expenditure in AKR/J mice without increasing uncoupling protein gene expression. *Journal of Nutrition* 2000; **130**: 2471–7.
  - 17 Akahoshi A, Koba K, Ichinose F, Kaneko M, Shimoda A, Nonaka K, *et al*. Dietary protein modulates the effect of CLA on lipid metabolism in rats. *Lipids* 2004; **39**: 25–30.
  - 18 Bee G. Dietary conjugated linoleic acids affect tissue lipid composition but not de novo lipogenesis in finishing pigs. *Animal Research* 2001; **50**: 383–99.
  - 19 Wiegand BR, Parrish Jr FC, Swan JE, Larsen ST, Baas TJ. Conjugated linoleic acid improves feed efficiency, decreases subcutaneous fat, and improves certain aspects of meat quality in stress-genotype pigs. *Journal of Animal Science* 2001; **79**(8): 2187–95.
  - 20 Dugan ME, Aalhus JL, Kramer JK. Conjugated linoleic acid pork research. *American Journal of Clinical Nutrition* 2004; **79**(6 Suppl.): 1212S–6S.
  - 21 Weber TE, Schinckel AP, Houseknecht KL, Richert BT. Evaluation of conjugated linoleic acid and dietary antibiotics as growth promotants in weanling pigs. *Journal of Animal Science* 2001; **79**(10): 2542–9.
  - 22 Chin SF, Storkson JM, Albright KJ, Cook ME, Pariza MW. Conjugated linoleic acid is a growth factor for rats as shown by enhanced weight gain and improved feed efficiency. *Journal of Nutrition* 1994; **124**: 2344–9.
  - 23 House RL, Cassidy JP, Eisen EJ, McIntosh MK, Odle J. Conjugated linoleic acid evokes de-lipidation through the regulation of genes controlling lipid metabolism in adipose and liver tissue. *Obesity Reviews* 2005; **6**(3): 247–58.
  - 24 Tricon S, Burdge GC, Kew S, Banerjee T, Russell JJ, Jones EL, *et al*. Opposing effects of cis-9,trans-11 and trans-10,cis-12 conjugated linoleic acid on blood lipids in healthy humans. *American Journal of Clinical Nutrition* 2004; **80**(3): 614–20.
  - 25 Tricon S, Burdge GC, Jones EL, Russell JJ, El-Khazen S, Moretti E, *et al*. Effects of dairy products naturally enriched with cis-9,trans-11 conjugated linoleic acid on the blood lipid profile in healthy middle-aged men. *American Journal of Clinical Nutrition* 2006; **83**(4): 744–53.
  - 26 Terpstra AH. Effect of conjugated linoleic acid on body composition and plasma lipids in humans: an overview of the literature. *American Journal of Clinical Nutrition* 2004; **79**(4): 352–61.
  - 27 Kamphuis MMJW, Lejeune MPM, Saris WHM, Westterp-Plantinga MS. The effect of conjugated linoleic acid supplementation after weight loss on body weight regain, body composition, and resting metabolic rate in overweight subjects. *International Journal of Obesity and Related Metabolic Disorders* 2003; **27**: 840–7.
  - 28 Larsen TM, Toubro S, Gudmundsen O, Astrup A. Conjugated linoleic acid supplementation for 1 y does not prevent weight or body fat regain. *American Journal of Clinical Nutrition* 2006; **83**(3): 606–12.
  - 29 Smedman A, Vessby B. Conjugated linoleic acid supplementation in humans – metabolic effects. *Lipids* 2001; **36**: 773–8.
  - 30 Blankson H, Stakkestad JA, Fagertun H, Thom E, Wadstein J, Gudmundsen O. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. *Journal of Nutrition* 2000; **130**: 2943–8.
  - 31 Riserus U, Smedman A, Basu S, Vessby B. Metabolic effects of conjugated linoleic acid in humans: the Swedish experience. *American Journal of Clinical Nutrition* 2004; **79**: 1146S–8S.
  - 32 Whigham LD, Watras AC, Schoeller DA. Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. *American Journal of Clinical Nutrition* 2007; **85**(5): 1203–11.
  - 33 Mougios V, Matsakas A, Petridou A, Ring S, Sagredos A, Melissopoulou A. Effect of supplementation with conjugated linoleic acid on human serum lipids and body fat. *The Journal of Nutritional Biochemistry* 2001; **12**: 585–94.
  - 34 Choi Y, Kim YC, Han YB, Park Y, Pariza MW, Ntambi JM. The trans-10,cis-12 isomer of conjugated linoleic acid downregulates stearoyl-CoA desaturase 1 gene expression in 3T3-L1 adipocytes. *Journal of Nutrition* 2000; **130**(8): 1920–4.
  - 35 Park Y, Storkson JM, Ntambi JM, Cook ME, Sih CJ, Pariza MW. Inhibition of hepatic stearoyl-CoA desaturase activity by trans-10,cis-12 conjugated linoleic acid and its derivatives. *Biochimica et Biophysica Acta* 2000; **1486**(2-3): 285–92.
  - 36 Park Y, Storkson JM, Albright KJ, Liu W, Pariza MW. Evidence that the trans-10,cis-12 isomer of conjugated linoleic acid induces body composition changes in mice. *Lipids* 1999; **34**(3): 235–41.
  - 37 Brown JM, Boysen MS, Jensen SS, Morrison RF, Storkson J, Lea-Currie R, *et al*. Isomer-specific regulation of metabolism and PPAR $\gamma$  signalling by CLA in human preadipocytes. *Journal of Lipid Research* 2003; **44**: 1287–300.
  - 38 Brown JM, Boysen MS, Chung S, Fabiya O, Morrison RF, Mandrup S, *et al*. Conjugated linoleic acid (CLA) induces human adipocyte delipidation: autocrine/paracrine regulation of MEK/ERK signaling by adipocytokines. *The Journal of Biological Chemistry* 2004; **279**: 26735–47.
  - 39 Tsuboyama-Kasaoka N, Takahashi M, Tanemura K, Kim HJ, Tange T, Okuyama H, *et al*. Conjugated linoleic acid supplementation reduces adipose tissue by apoptosis and develops lipodystrophy in mice. *Diabetes* 2000; **49**(9): 1534–42.
  - 40 Nelson-Dooley C, Della-Fera MA, Hamrick M, Baile CA. Novel treatments for obesity and osteoporosis: targeting apoptotic pathways in adipocytes. *Current Medicinal Chemistry* 2005; **12**(19): 2215–25.
  - 41 Miner JL, Cederberg CA, Nielsen MK, Chen X, Baile CA. Conjugated linoleic acid (CLA), body fat, and apoptosis. *Obesity Research* 2001; **9**: 129–34.
  - 42 Evans M, Geigerman C, Cook J, Curtis L, Kuebler B, McIntosh M. Conjugated linoleic acid suppresses triglyceride accumulation and induces apoptosis in 3T3-L1 preadipocytes. *Lipids* 2000; **35**: 899–910.
  - 43 Hargrave KM, Meyer BJ, Li C, Azain MJ, Baile CA, Miner JL. Influence of dietary conjugated linoleic acid and fat source on body fat and apoptosis in mice. *Obesity Research* 2004; **12**(9): 1435–44.
  - 44 Chung S, Brown JM, Provo JN, Hopkins R, McIntosh MK. Conjugated linoleic acid promotes human adipocyte insulin resistance through NF $\kappa$ B-dependent cytokine production. *The Journal of Biological Chemistry* 2005; **280**(46): 38445–56.
  - 45 West DB, Delany JP, Camet PM, Blohm F, Truett AA, Scimeca J. Effects of conjugated linoleic acid on body fat and energy metabolism in the mouse. *The American Journal of Physiology* 1998; **275**(3 Pt 2): R667–72.
  - 46 Ohnuki K, Haramizu S, Oki K, Ishihara K, Fushiki T. A single oral administration of conjugated linoleic acid

- enhanced energy metabolism in mice. *Lipids* 2001; **37**: 583–7.
- 47 Ealey KN, El Sohemy A, Archer MC. Effects of dietary conjugated linoleic acid on the expression of uncoupling proteins in mice and rats. *Lipids* 2002; **37**: 853–61.
  - 48 Takahashi Y, Kushihiro M, Shinohara K, Ide T. Dietary conjugated linoleic acid reduces body fat mass and affects gene expression of proteins regulating energy metabolism in mice. *Comparative Biochemistry and Physiology* 2002; **133**: 395–404.
  - 49 Clement L, Poirier H, Niot I, Bocher V, Guerre-Millo M, Krief S, *et al.* Dietary trans-10,cis-12 conjugated linoleic acid induces hyperinsulinemia and fatty liver in the mouse. *Journal of Lipid Research* 2002; **43**: 1400–9.
  - 50 Degrace P, Demizieux L, Gresti J, Chardigny JM, Sébédio JL, Coulet P. Hepatic steatosis is not due to impaired fatty acid oxidation capacities in C57BL/6j mice fed the conjugated trans-10,cis-12-isomer of linoleic acid. *Journal of Nutrition* 2004; **134**: 861–7.
  - 51 Peters JM, Park Y, Gonzalez FJ, Pariza MW. Influence of conjugated linoleic acid on body composition and target gene expression in peroxisome proliferator-activated receptor alpha-null mice. *Biochimica et Biophysica Acta* 2001; **1533**: 233–42.
  - 52 Moya-Camarena SY, Vanden Heuvel JP, Blanchard SG, Leesnitzer LA, Belury MA. Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPAR-alpha. *Journal of Lipid Research* 1999; **40**: 1426–33.
  - 53 Lee KN, Pariza MW, Ntambi JM. Conjugated linoleic acid decreases hepatic stearoyl-CoA desaturase mRNA expression. *Biochemical and Biophysical Research Communications* 1998; **248**(3): 817–21.
  - 54 Kang K, Miyazaki H, Ntambi JM, Pariza MW. Evidence that the anti-obesity effect of conjugated linoleic acid is independent of effects on stearoyl-CoA desaturase1 expression and enzyme activity. *Biochemical and Biophysical Research Communications* 2004; **315**: 532–7.
  - 55 de Deckere EA, van Amelsvoort JM, McNeill GP, Jones P. Effects of conjugated linoleic acid (CLA) isomers on lipid levels and peroxisome proliferation in the hamster. *British Journal of Nutrition* 1999; **82**(4): 309–17.
  - 56 Ostrowska E, Muralitharan M, Cross RF, Bauman DE, Dunshea FR. Dietary conjugated linoleic acids increase lean tissue and decrease fat deposition in growing pigs. *Journal of Nutrition* 1999; **129**(11): 2037–42.
  - 57 Ostrowska E, Suster D, Muralitharan M, Cross RF, Leury BJ, Bauman DE, *et al.* Conjugated linoleic acid decreases fat accretion in pigs: evaluation by dual-energy X-ray absorptiometry. *British Journal of Nutrition* 2003; **89**(2): 219–29.
  - 58 Riserus U, Arner P, Brismar K, Vessby B. Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome. *Diabetes Care* 2002; **25**: 1516–21.
  - 59 Noone EJ, Roche HM, Nugent AP, Gibney MJ. The effect of dietary supplementation using isomeric blends of conjugated linoleic acid on lipid metabolism in healthy human subjects. *British Journal of Nutrition* 2002; **88**: 243–51.
  - 60 Moloney F, Yeow TP, Mullen A, Nolan JJ, Roche HM. Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus. *American Journal of Clinical Nutrition* 2004; **80**(4): 887–95.
  - 61 Steck SE, Chalecki AM, Miller P, Conway J, Austin GL, Hardin JW, *et al.* Conjugated linoleic acid supplementation for twelve weeks increases lean body mass in obese humans. *Journal of Nutrition* 2007; **137**(5): 1188–1193.
  - 62 Petridou A, Mougios V, Sagredos A. Supplementation with CLA: isomer incorporation into serum lipids and effect on body fat of women. *Lipids* 2003; **38**(8): 805–11.
  - 63 Benito P, Nelson GJ, Kelley DS, Bartolini G, Schmidt PC, Simon V. The effect of conjugated linoleic acid on plasma lipoproteins and tissue fatty acid composition in humans. *Lipids* 2001; **36**: 229–36.
  - 64 Arbones-Mainar JM, Navarro MA, Guzman MA, Arnal C, Surra JC, Acin S, *et al.* Selective effect of conjugated linoleic acid isomers on atherosclerotic lesion development in apolipoprotein E knockout mice. *Atherosclerosis* 2006; **189**(2): 318–27; Epub 2006 Mar 13.
  - 65 Riserus U, Vessby B, Arner P, Zethelius B. Supplementation with trans10, cis12-conjugated linoleic acid induces hyperproinsulinaemia in obese men: close association with impaired insulin sensitivity. *Diabetologia* 2004; **47**(6): 1016–19.
  - 66 Wargent E, Sennitt MV, Stocker C, Mayes AE, Brown L, O'Dowd J, *et al.* Prolonged treatment of genetically obese mice with conjugated linoleic acid improves glucose tolerance and lowers plasma insulin concentration: possible involvement of PPAR activation. *Lipids in Health and Disease* 2005; **4**(1): 3.